Protagonist Therapeutics opened lower at $134.16, compared with its previous close of $134.86. In the last trading session, the stock traded between $131.27 and $138.82. It showed a sideways intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Protagonist Therapeutics is now worth
$ 370.65
Giving a profit of
$ 270.65 (270.65%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 13 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.50 (-0.37%)
Day High
$138.82
Day Low
$131.27
Day Open
$134.16
Prev Close
$134.86
Volume
4,32,994
1W Return
-6.42%
1M Return
-7.30%
3M Return
-9.36%
6M Return
29.82%
1Y Return
57.04%
Fundamentals
Market Cap ($ Mn)
8,770
PE Ratio
140.13
PB Ratio
11.09
PEG Ratio
3.58
ROE
-19.76%
ROCE
-23.48%
EPS (TTM)
$3.40
Investment Returns
1 Week
-6.42%
1 Month
-7.30%
3 Months
-9.36%
6 Months
29.82%
9 Months
60.93%
Financials
Quarterly
All values in $ Mn
28.3
Mar 25
5.5
Jun 25
4.7
Sep 25
7.4
Dec 25
213.5
Jun 26
274.4
Sep 26
Updates
7Nov
HC Wainwright raises Protagonist Therapeutics price target to $221
HC Wainwright & Co. maintains a Buy rating on Protagonist Therapeutics. Price target raised to $221 from $170 by analyst Douglas Tsao.
6 days ago
21Oct
TD Cowen raises Protagonist Therapeutics price target to $160
TD Cowen raised the price target for Protagonist Therapeutics to $160. The previous price target was set at $155. Analyst Tara Bancroft maintained a Buy rating on the stock.
22 days ago
28Sep
Protagonist Therapeutics turns $100 into $668.69 over 10 years
A $100 investment in Protagonist Therapeutics from 10 years ago is now worth $668.69. The stock delivered an average annual return of 20.58%, outperforming the market by 6.99%. Current market capitalization stands at $9.22 billion with a share price of $142.50.
1mo ago
9Sep
Protagonist Therapeutics authorizes $300 million share buyback plan
Protagonist Therapeutics board approves $300 million share buyback. Repurchases will target outstanding common stock. Program execution depends on market conditions and discretion.
2mo ago
2Sep
Protagonist Therapeutics CEO to speak at Citi, Cantor healthcare events
CEO Dinesh V. Patel to hold fireside chats at Citi and Cantor conferences in New York. Sessions scheduled for September 9 and September 10, 2026, with live webcasts available. Company highlights FDA-approved ICOTYDE and MIMRYLO under partnerships with J&J and Takeda. ICOTYDE launched in U.S. in March 2026 for plaque psoriasis treatment.
2mo ago
29Aug
Protagonist Therapeutics secures FDA approval for MIMRYLO
FDA approves MIMRYLO for polycythemia vera, triggering $275M in payments to Protagonist. Deal includes up to $875M in future milestones and 14%-29% tiered royalties on net sales. Phase 3 VERIFY study showed 76.9% response rate vs 32.9% for placebo in weeks 20-32. Takeda assumes global commercialization after Protagonist's April 2026 opt-out election.
